CoreAge Rx vs Invyncible
Two GLP-1 providers, one scoreboard. We put CoreAge Rx and Invyncible head-to-head on the published Brief Score — the same six factors, scored the same way.
CoreAge Rx
The verdict
CoreAge Rx takes this head-to-head.
CoreAge Rx scores 94 to 59 on our six-factor Brief Score — One price on both molecules that does not climb as you titrate — but the headline $99 and $149 are annual-plan rates, paid in full up front.
That doesn't make Invyncible a bad call — it's best for readers who want to read the price of every dose program, and the pharmacy behind it, before starting an intake. Weigh the six factors below against your own priorities before you decide.
Why CoreAge Rx leads: it's our #1 here — one flat, no-step-up price on both molecules, nationwide, and the steadiest line on our tracker.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.
Factor by factor
Both providers scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.
Price, coverage & the tracker
| CoreAge Rx | Invyncible | |
|---|---|---|
| Brief Score | 94/100 (A) | 59/100 (C) |
| Semaglutide | $99/mo only on a 12-month plan paid in full ($1,188 in one charge); month-to-month rate not published | From $149/mo (0.45 mg dose, compounded with glycine + B12) |
| Tirzepatide | $149/mo only on a 12-month plan paid in full ($1,788 in one charge); month-to-month rate not published | From $180/mo (2.5 mg weekly, 4-week program, compounded) |
| Coverage | US only; restrictions by state, confirmed at intake | 46 states plus DC |
| Brand-name access | Compounded only | Yes |
| Oral / sublingual | Injection only | Yes |
| On the tracker | Stableprice stable | Newnew to the tracker, no prior reading |
CoreAge Rx: Headline unchanged for a third straight cycle. The $99 and $149 are the 12-month prepay rates; CoreAge publishes no month-to-month price.
Invyncible: The first reading of this row recorded From $192/mo and reported that no price was published at all, which was wrong — it was read off the company homepage, which sells nothing. Re-read against the product catalog, the line is From $149/mo (0.45 mg dose, compounded with glycine + B12). Treat that as the first honest reading; there is no earlier one worth comparing against.
Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.